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A small fraction of breast cancers (~1–5%)1–3 are attributed to familial 
mutations in the BRCA1 and BRCA2 cancer susceptibility genes. 
Heterozygous germline mutations in BRCA1 and BRCA2 confer 
elevated lifetime risks of breast, ovarian and other cancers4,5. BRCA1 
Approximately 1–5% of breast cancers are attributed to 
inherited mutations in BRCA1 or BRCA2 and are selectively 
sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors.  
In other cancer types, germline and/or somatic mutations  
in BRCA1 and/or BRCA2 (BRCA1/BRCA2) also confer  
selective sensitivity to PARP inhibitors. Thus, assays to detect 
BRCA1/BRCA2-deficient tumors have been sought. Recently, 
somatic substitution, insertion/deletion and rearrangement 
patterns, or ‘mutational signatures’, were associated with 
BRCA1/BRCA2 dysfunction. Herein we used a lasso logistic 
regression model to identify six distinguishing mutational 
signatures predictive of BRCA1/BRCA2 deficiency. A weighted 
model called HRDetect was developed to accurately detect 
BRCA1/BRCA2-deficient samples. HRDetect identifies  
BRCA1/BRCA2-deficient tumors with 98.7% sensitivity  
(area under the curve (AUC) = 0.98). Application of this  
model in a cohort of 560 individuals with breast cancer,  
of whom 22 were known to carry a germline BRCA1 or BRCA2 
mutation, allowed us to identify an additional 22 tumors 
with somatic loss of BRCA1 or BRCA2 and 47 tumors with 
functional BRCA1/BRCA2 deficiency where no mutation was 
detected. We validated HRDetect on independent cohorts of 
breast, ovarian and pancreatic cancers and demonstrated  
its efficacy in alternative sequencing strategies. Integrating  
all of the classes of mutational signatures thus reveals  
a larger proportion of individuals with breast cancer harboring 
BRCA1/BRCA2 deficiency (up to 22%) than hitherto 
appreciated (~1–5%) who could have selective therapeutic 
sensitivity to PARP inhibition.
and BRCA2 proteins have multiple, distinct roles in maintaining 
genome integrity, particularly through homologous recombination 
(HR)-mediated double-strand break (DSB) repair6. These classical 
tumor-suppressor genes usually lose the wild-type allele during tumor-
igenesis to become fully inactivated7. BRCA1- and BRCA2-null tumors 
are thus deficient in HR and are selectively sensitive to compounds that 
increase the demand on HR8. PARP inhibitors are an example of thera-
peutic compounds that cause replication fork stalling and collapse, 
leading to increased DSBs9. The inability to perform HR-dependent 
DSB repair ultimately leads to selective tumor cell death10,11.
Preclinical studies and phase I and II breast and ovarian cancer 
clinical trials12,13 have shown PARP inhibitor efficacy in familial 
BRCA1- and BRCA2-mutant patients. However, PARP inhibition 
has applications beyond the treatment of germline-mutated tumors14. 
Effective PARP inhibition maintenance therapy has been demonstrated 
in high-grade serous ovarian cancer with germline or somatic BRCA1 
or BRCA2 mutations15. Thus, extensive efforts have been put into 
identifying the molecular features of tumors that are BRCA1 or BRCA2 
deficient—a defect historically referred to as ‘BRCAness’—whether 
the genes are inactivated through germline, somatic or secondary 
means, including promoter DNA hypermethylation or inactivation 
of a related gene in the HR pathway.
Gene-specific sequencing strategies, including sequencing all 
known HR genes, multiplex-ligation-dependent probe amplifica-
tion (MLPA)16, promoter hypermethylation assays17, identification 
of transcriptional metagene signatures18–20, copy-number-based 
methods (for example, to determine the homologous recombination 
deficiency (HRD) index and genomic ‘scars’)21–23 and functional assays 
of HR competence24, have been developed to detect BRCA1/BRCA2 
deficiency. However, the indices from these methods have had limited 
predictive success. A recent review suggests that a good predictor 
of the biological status of an HR-deficient tumor is essential, as the 
cohort of tumors that demonstrate BRCAness and could be selectively 
sensitive to PARP inhibitors is likely not limited to the small propor-
tion of familial breast and ovarian cancers with BRCA1 or BRCA2 
mutations but extends to a larger fraction of sporadic breast and ovar-
ian cancers, as well as other cancer types25.
Recent advances in sequencing technology26 have greatly reduced 
sequencing costs, permitting whole-genome sequencing (WGS) for 
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the detection of all somatic mutations, including base substitutions, 
insertions/deletions (indels), rearrangements and copy number aber-
rations, in human cancers. Deep analysis reveals patterns of muta-
tions, or somatic mutational signatures, which are the physiological 
readout of the DNA damage and DNA repair processes that have 
occurred through tumorigenesis27–31. These patterns are indicators 
of past and ongoing exposures, whether to environmental insults, 
such as UV radiation, or to endogenous biochemical degradation and 
deficiencies of DNA repair pathways like HR.
We reason that mutational signatures that report BRCA1/BRCA2 
deficiency in germline-mutated tumors could be used as a predic-
tor of other tumors that also have this deficiency. Previously, base- 
substitution signature 3 was shown to distinguish germline 
BRCA1/BRCA2-null cancers from sporadic cancers in a small subset 
of breast cancers29,30 and was subsequently extended to pancreatic32,33, 
ovarian34 and stomach35 cancers. However, selecting a cutoff to dis-
criminate BRCA1/BRCA2-deficient from BRCA1/BRCA2-proficient 
cancers is not straightforward when using this signature alone. Recent 
characterization of a large cohort of WGS breast cancers27,28 has 
provided new insights into how these cancers can be distinguished. 
A defect in a single gene such as BRCA1 or BRCA2 does not result in a 
single signature—it gives rise to at least five mutational signatures of all 
classes, including base substitutions, indels and rearrangements27,28. 
Unlike most biomarkers, these multiple mutational signatures are 
the direct consequence of abrogation of DSB repair pathways. Thus, 
in the current analysis, we exploit this observation to quantitatively 
define the genomic features of BRCA1/BRCA2 deficiency and present 
a WGS-based predictor with remarkable performance for detection 
of HR-deficient tumors.
RESULTS
Quantitatively defining features of BRCAness
Twenty-four individuals carrying inherited predisposition mutations 
in BRCA1 (n = 5) and BRCA2 (n = 19) were recruited into a breast 
cancer genome sequencing study involving 560 individuals27. Loss 
of the wild-type allele, which was predicted to result in complete 
inactivation of the relevant protein, was observed in 22 of the 
24 breast cancers.
These 22 tumors had a distinguishing genomic profile: over- 
representation of base-substitution signature 3 or 8, an excess of 
large deletions (>3 bp) with microhomology at the junction of 
the deletion, rearrangement signature 5 and copy number pro-
files associated with the widespread loss of heterozygosity (Fig. 1). 
Additionally, BRCA1-null tumors mainly had an excess of rearrange-
ment signature 3 mutations (characterized by short <10-kb tandem 
duplications) and a lesser contribution of rearrangement signature 1 
mutations (typified by long >100-kb tandem duplications)27.
The 22 BRCA1- or BRCA2-null tumors were used in a first train-
ing set to quantitatively define features of BRCA1/BRCA2 deficiency. 
They were contrasted with a cohort of 235 cases of sporadic breast 
cancer with quiescent genomic profiles, which are distinct from the 
profiles of BRCA1/BRCA2-null cancers.
Somatic variants of all classes of mutation had been previously 
called. Twelve base-substitution, two indel and six rearrange-
ment mutational signatures were previously extracted, and HRD 
copy number indices were obtained (Supplementary Table 1). 
A lasso logistic regression model was applied to counts of mutational 
signatures and HRD indices that were log transformed and nor-
malized to permit comparability between genomic parameters 
(Supplementary Table 2).
An iterative tenfold nested cross-validation strategy was adopted, 
where 90% of samples were used for model parameter selection and 
the weights for each parameter were tested on the remaining 10% of 
samples. This was performed to ensure that the parameters identi-
fied as putative predictors of BRCA1/BRCA2 deficiency were robust 
and generalizable.
Five distinguishing parameters with different individual weights 
were found to convey the greatest difference between BRCA1/BRCA2- 
deficient cancers and sporadic breast cancers: microhomology- 
mediated indels, the HRD index, base-substitution signature 3, 
rearrangement signature 3 and rearrangement signature 5 
(Supplementary Table 2).
Identification of additional BRCA1- and BRCA2-null tumors
The selected parameters were applied across the cohort of 560 breast 
cancers to test the performance of our model in predicting BRCA1/
BRCA2 deficiency and to detect other cancers with characteristics simi-
lar to germline BRCA1/BRCA2-null tumors (see Fig. 2 for the workflow; 
Supplementary Table 2 and Supplementary Fig. 1). The resulting 
distribution of probabilities of BRCA1/BRCA2 deficiency was a strik-
ingly steep sigmoidal curve with a clear distinction between the indi-
viduals predicted to have high and low probabilities of BRCA1/BRCA2 
deficiency. Apart from the 22 positive controls from the training 
set, 90 of 538 additional tumor samples were identified as having 
a probability of BRCA1/BRCA2 deficiency exceeding 0.7, bringing 
the total proportion of patients predicted to have a high level of 
BRCA1/BRCA2 deficiency to 20%.
This result prompted us to look for additional BRCA1 and BRCA2 
mutations (germline and somatic) in the cohort of 560 patients. 
Thirty-three patients were found to carry pathogenic germline vari-
ants in BRCA1 or BRCA2 with corresponding somatic inactivation of 
the second allele. This more than doubles the number of individuals 
harboring familial cancer predisposition alleles relative to the number 
who were known to have germline BRCA1 or BRCA2 mutations when 
originally recruited into the study, carrying important clinical genetic 
counseling implications and potential for active surveillance and/or 
treatment choices for affected individuals and their families.
Twenty-two individuals had early, clonal somatic BRCA1 or BRCA2 
mutations (n = 8) or promoter DNA hypermethylation of BRCA1  
(n = 14) with inactivation of the second allele. The remaining tumors 
with a probability of BRCA1/BRCA2 deficiency exceeding 0.7 did not 
demonstrate biallelic inactivation of BRCA1 or BRCA2, although DNA 
methylation data were not available for a subset of individuals.
Six BRCA1-null samples had probabilities of 0.006–0.64 and 
were missed because the algorithm had been trained on a small 
cohort of 5 BRCA1-mutant tumors of the total 22 in the training set, 
suggesting that algorithm retraining on a larger and more balanced 
cohort was prudent.
HRDetect: predictor of BRCA1/BRCA2 deficiency in cancer
Given that additional individuals were identified as null for BRCA1 or 
BRCA2, we performed another iteration of the lasso logistic regression 
model on a larger, better-powered training set comprising 77 samples 
(22 with known germline mutations, 33 with new germline mutations 
and 22 with somatic mutations) (Fig. 2).
Reassuringly, the same genomic features were identified as predictive 
parameters that had been observed for the 22 germline-null samples, 
with the addition of base-substitution signature 8. These features, ranked 
by decreasing weight, included microhomology-mediated deletions 
(2.398), base-substitution signature 3 (1.611), rearrangement signature 
   
3 (1.153), rearrangement signature 5 (0.847), HRD index (0.667) and 
base-substitution signature 8 (0.091) (Fig. 2b and Supplementary 
Table 3). Acknowledging the imbalance in the numbers of BRCA1- or 
BRCA2-null cancers versus controls, supervised learning was repeated 
with a 1:1 ratio of these cases and controls. Differences between this 
assessment and the original one (77 null cancers:234 controls) were 
insignificant, verifying the stability of the six parameters critical for 
distinguishing BRCA1/BRCA2-deficient tumors. With a larger data 
set available, we permitted identification of interactions between 
genomic covariates in order to discover potentially augmented effects 
from cooperating signatures. Although correlations were observed 
(Supplementary Fig. 2), the performance including interactions did 
not improve on predictions made by the model without interactions. 
Therefore, we opted for the simpler model, keeping each genomic 
parameter independent. Thus, we finalized our predictor of BRCA1/
BRCA2 deficiency, termed HRDetect, on this set.
HRDetect was reapplied on the cohort of 560 cases of breast cancer 
(Fig. 3) and showed excellent performance, as demonstrated by a receiver 
operating characteristic (ROC) curve with an area under the curve 
(AUC) of 0.98 (Fig. 4). This result is unlikely to be bettered, emphasizing 
the value of utilizing multiple mutational signatures as a readout 
of BRCA1/BRCA2 deficiency. Reinforcing this point, no individual 
genomic parameter performed as well as all six genomic signatures 
incorporated together in HRDetect (Fig. 4). In particular, HRDetect 
is superior to current methods of assessing BRCA1/BRCA2 deficiency, 
specifically, genomic-scar-based indexes21–23 such as the HRD score 
(sensitivity of HRD score = 0.6; the ROC curves in Fig. 4 compare 
HRDetect against HRD score alone and other mutational signatures 
individually).
Using a probabilistic cutoff of 0.7, HRDetect predicted BRCA1/
BRCA2 deficiency with a sensitivity of 98.7% in the cohort of 560 
individuals. HRDetect identified a total of 124 samples with a 
score exceeding 0.7, including an additional 47 samples with a high 
probability of BRCA1/BRCA2 deficiency. These remaining tumors 
(5/340 estrogen receptor (ER)-positive and 42/143 ER-negative 
tumors) with high scores and neither germline nor somatic BRCA1 
or BRCA2 mutations, and in which promoter hypermethylation of 
BRCA1 was either not observed (n = 10) or not available for assess-
ment (n = 37), were investigated for the inactivation of other genes 
involved in HR repair and for other germline susceptibility alleles.
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Figure 1 Whole-genome profiling depicts differences between patients with BRCA1/BRCA2-mutated tumors and sporadic tumors. Examples of genome 
plots are shown for a typical sporadic breast cancer tumor (left), a BRCA1 germline-null tumor (middle) and a BRCA2 germline-null tumor (right). The 
features depicted in the Circos plots from the outermost rings moving inwards are (i) the karyotypic ideogram; (ii) base substitutions, plotted as rainfall 
plots (log10 (intermutation distance) on the radial axis; dot color: blue, C>A; black, C>G; red, C>T; gray, T>A; green, T>C; pink, T>G); (iii) insertions 
shown as short green lines; (iv) deletions shown as short red lines; (v) major (green blocks, gain) and minor (red blocks, loss) copy number alleles; and 
(vi) rearrangements shown as central lines (green, tandem duplications; red, deletions; blue, inversions; purple, interchromosomal events). Driver genes 
with mutations in breast cancer are labeled around each Circos plot. Below each Circos plot are histograms showing mutation counts for each mutation 
class: the topmost histogram shows the number of mutations contributing to each substitution signature; the middle histogram represents indel 
patterns; and the bottom histogram shows the number of rearrangements contributing to each rearrangement signature.
   
Other genetic factors and BRCAness
Of these 47 samples with high HRDetect scores and without bial-
lelic BRCA1 or BRCA2 mutations, 3 had mutations in HR genes. One 
individual, PD4875a, exhibited a high HRDetect score (0.94) and had 
a profile that is typically associated with BRCA2 nullness. Although 
she carried a germline BRCA2 mutation, the other parental allele 
was retained36. This patient was thus the exception where genetic 
BRCA2 nullness could not be proven in the tumor. Inactivation 
of the wild-type allele by alternative means cannot be excluded. 
This patient also carried a germline truncating mutation in BRIP1  
(a gene associated with moderate penetrance breast cancer risk) 
with loss of the second allele; however, with only a single example 
of a truncating BRIP1 mutation, the significance of this mutation 
is unclear. Otherwise, all other tumors with monoallelic germline 
or somatic inactivation of BRCA1 or BRCA2 were associated with 
low HRDetect scores (13 individuals in total: 4 with germline inac-
tivation, 7 with somatic inactivation and 2 with BRCA1 promoter 
hypermethylation) (Supplementary Table 4).
Two individuals (PD24205a and PD24212a) had somatic monoal-
lelic truncating mutations in PALB2 (also associated with moder-
ate penetrance breast cancer risk). A third individual, PD11340a, 
who had a low HRDetect score also had a deleterious somatic monoal-
leleic essential-splice-site PALB2 mutation. Given the small numbers 
of individuals with mutations in this gene, we would interpret the 
contribution of PALB2 mutations with caution, as other modes of 
BRCA1/BRCA2 inactivation or inactivation of other genes related to 
the HR pathway could underlie the observations in these patients.
Interestingly, monoallelic somatic inactivating mutations of other 
HR repair genes including ATR (PD14457a, PD23564a, PD5956a) and 
ATM (PD5937a) were not associated with high scores of BRCA1/BRCA2 
deficiency. Furthermore, none of the genes from the list of HR genes 
(RAD51C, RAD50, CHEK2 and FANCA–PALB2 (FANCN), the FANC 
group of genes) was identified as a contributor among tumors with 
high HRDetect scores. Notably, high- and moderate-penetrance germ-
line breast cancer susceptibility alleles, including for TP53, PTEN, 
ATM, CHEK2, ATR, RAD50, CDH1, STK11 and PALB2, whether 
in the context of monoallelic or biallelic inactivation, were not 
associated with either a genomic profile or a high probability of 
BRCA1/BRCA2 deficiency.
These results first emphasize the importance of knowing the status 
of the alternative parental allele in the interpretation of mutation data 
(Supplementary Table 4). Second, they highlight that nearly one-
third of tumors with high HRDetect scores predicting BRCA1/BRCA2 
deficiency cannot be authenticated as BRCA1 or BRCA2 null through 
genetic and/or epigenetic means. Yet, given the striking resemblance 
of these tumors to BRCA1- and BRCA2-null tumors, it is intriguing 
to consider that these cancers are biologically comparable and likely 
to respond similarly as BRCA1- and BRCA2-null cancers, particularly 
to PARP inhibition.
Validation of HRDetect in a new cohort of 80 WGS breast cancers
As a validation exercise, HRDetect was applied to a new cohort of 
WGS breast cancers that were mainly ER positive and HER2 negative 
from 80 individuals (Fig. 4 and Supplementary Table 5). HRDetect 
successfully identified one germline BRCA1 mutation carrier and 
five BRCA2 mutation carriers (four germline and one somatic) with 
associated loss of the wild-type allele. One individual, PD14434a, 
carried a germline essential-splice-site mutation with loss of the alter-
native parental allele but fell short of the HRDetect cutoff of 0.7. Two 
samples, one with a germline and one with a somatic BRCA2 muta-
tion, retained the alternative allele and were correctly assigned low 
HRDetect scores. Thus, the sensitivity of HRDetect on this validation 
cohort was high at 86%.
Performance of HRDetect with alternative sequencing strategies
To explore the performance of HRDetect with alternative sequencing 
strategies, we performed an in silico experiment, randomly downsam-
pling the sequences of the 560 high-coverage (30- to 40-fold) WGS 
breast cancers in order to generate low-coverage (10-fold; range 9.9- to 
10.5-fold) WGS sequence files for analysis (Supplementary Table 6). 
 Somatic mutations were called across the downsampled sequences, 
signatures and HRD indices were extracted and the performance 
of HRDetect was tested. In theory, the absolute detection of every 
somatic change is not obligatory, as long as some mutations that are 
representative of the overarching mutation patterns are present.
As expected, the numbers of base substitutions, indels and rear-
rangements were consistently lower in the downsampled in silico 
experiment of all samples when compared to the original high- 
coverage experiment. Nevertheless, all 12 base-substitution, 2 indel 
and 6 rearrangement signatures were detectable, at approximately 
the same proportions per sample, albeit they were present at reduced 
absolute numbers (Supplementary Fig. 3). Additionally, copy number 
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Figure 2 Workflow for developing HRDetect. (a) Workflow of the steps involved in the development of the HRDetect predictor. (I) Initial training  
using 22 known germline BRCA1/BRCA2-null samples. (II) Retraining using 77 BRCA1/BRCA2-null samples to produce the final HRDetect predictor. 
(III) Validation on a further set of breast cancers and application to other data sets. (b) Box plots of the weights for the genomic features contributing 
to the HRDetect predictor. The range of values from 10 replicates of training in cross-validation using 311 breast cancer samples (77 BRCA1/BRCA2-
null samples and 234 quiescent tumors) is shown. Red crosses indicate the final weights used in HRDetect. In the box plots, the midline represents 
the median, the two edges of the box represent the lower and upper interquartile range (IQR), upper whisker = min(max(x), Q3 + 1.5 × IQR) and lower 
whisker = max(min(x), Q1 − 1.5 × IQR), and the dots are outliers beyond the whiskers.
   
analysis showed good concordance for overall HRD scores (r = 0.63) 
between the high- and low-coverage genomes. Thus, despite the 
reduction in sensitivity for individual somatic mutations, the detec-
tion of overarching mutation signatures remained relatively secure.
At an absolute probability cutoff of 0.7, the sensitivity for 
detection of BRCA1/BRCA2-defective cancers in a low-coverage 
genome sequencing experiment remained high at 86% (Fig. 4). 
The concordance in HRDetect predictions between high- and 
low-coverage sequencing experiments was excellent (r = 0.96). 
Low-coverage genome sequences may thus be adequate for HRDetect 
to report deficiency of BRCA1/BRCA2.
In contrast, when HRDetect was used to assess BRCA1/BRCA2 
deficiency in data that were representative of only coding sequences 
(whole-exome sequencing, WES), the sensitivity of detection 
was affected considerably, falling to 46.8%. This is because data on 
essential predictor components such as rearrangement signatures 3 
and 5 are not available by WES, and substitutions/indels are restricted 
to only 1–1.5% of the footprint of the genome (Supplementary Note). 
When the HRDetect algorithm was retrained taking WES-based 
data alone as input, the performance of the classifier was improved 
(sensitivity, 73%, correctly identifying 56 of 77 BRCA1- or BRCA2-
null tumors), although at the cost of calling 12 additional samples 
that were not previously identified as BRCA1/BRCA2 deficient 
(Supplementary Table 7).
Application of HRDetect to predict BRCAness in other  
types of cancer
HRDetect was applied to other WGS cancers, including pancreatic 
and ovarian cancers, to assess the predictor’s generalizability across 
tumor types32–34. Available BAM files were analyzed using our somatic 
mutation calling pipeline, mutational signatures were extracted and 
copy number profiles were obtained.
The ovarian cancer cohort comprised 73 samples. Using a thresh-
old of 0.7, 46 (63%) were identified as having a high probability of 
BRCA1/BRCA2 deficiency. Of these, 30 were confirmed as having 
germline or somatic BRCA1 or BRCA2 mutations with loss of the 
wild-type parental allele (14 with germline mutations, 6 with somatic 
mutations and 10 with altered DNA methylation) (Supplementary 
Table 8). No BRCA1/BRCA2-null ovarian samples were found to 
have a low HRDetect score. Thus, again, HRDetect has a sensitiv-
ity of detecting BRCA1/BRCA2-null cancers approaching 100%, and 
it uncovered 16 additional individuals in the ovarian cancer cohort 
as HR deficient.
The pancreatic cancer cohort comprised 96 samples. Eleven 
(11.5%) were found to have a high HRDetect score. Five were mutated 
for BRCA1 or BRCA2 (three with germline mutations and two with 
somatic mutations) and had lost the wild-type allele, and one had 
retained the wild-type allele. Epigenetic data were not available to 
interrogate the status of the remaining five samples. Three samples had 
BRCA2 mutations, but these did not show convincing evidence of loss 
of the wild-type allele and had low HRDetect scores (Supplementary 
Table 8). Thus, HRDetect had a sensitivity approaching 100% in this 
pancreatic cancer cohort and identified five additional patients with 
potential HR deficiency.
Overall, HRDetect had excellent sensitivity for these other tumor 
types. However, the distributions of HRDetect scores were slightly 
different (Fig. 4c). When more samples become available, thus 
increasing power for analysis, a reappraisal of HRDetect param-
eters per tissue type may be necessary to fine-tune performance in 
different tissue types.
Strengths of HRDetect scores and their relevance to 
accelerating clinical application
Routine clinical pathology practice involves the storage of tumor 
material using formalin fixation and paraffin embedding (FFPE) 
methods. To explore the performance of HRDetect on FFPE tissue 
samples (Fig. 5), we obtained nucleic acids derived from an FFPE 
sample from a patient with a germline BRCA1 mutation. WGS was 
performed, somatic mutations were called and mutational signa-
tures were extracted. HRDetect correctly reported a high probability 
(0.94) of BRCA1/BRCA2 deficiency, despite an overwhelming FFPE-
related sequencing artifact (Fig. 5 and Supplementary Table 9) that 
compromised substitution signature extraction, resulting in the 
absence of base-substitution signature 3. Small amounts of the cor-
rect combination of other critically distinguishing signatures still 
generated a strong probabilistic prediction.
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Figure 3 HRDetect as a probabilistic classifier. (a) Pie charts depicting the BRCA1 and BRCA2 mutation status of samples in the data set of 560 breast 
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of the BRCA1 promoter with loss of the second allele; black, monoallelic germline or somatic BRCA1/BRCA2 mutation carriers retaining the second 
allele; gray, samples in which no BRCA1/BRCA2 mutation has been detected. (b) The HRDetect scores of 560 breast cancer samples ordered from 
lowest to highest score across the x axis from left to right. Colored bars represent both samples with monoalleleic mutations and those with loss of 
the second allele: purple, previously known carriers of germline BRCA1/BRCA2 mutations (24 in total, of which 22 have biallelic loss and 2 have 
monoalleleic loss); blue, newly discovered carriers of germline BRCA1/BRCA2 mutation (36 in total, of which 33 have biallelic loss and 3 have 
monoalleleic loss); orange, carriers of somatic germline BRCA1/BRCA2 mutations and DNA hypermethylation of the BRCA1 promoter (31 in total, 
of which 22 have biallelic loss and 9 have monoalleleic loss); black diamonds above the bars indicate samples with monoallelic germline or somatic 
BRCA1/BRCA2 mutant alleles that retained the second allele (14 in total).
   
Biological hypermutation phenomena occur in human cancers, 
and mutational processes, such as those due to the APOBEC 
family of cytidine deaminases, are not uncommon. We found that 
BRCA1/BRCA2-deficient cancers remained consistently identified by 
HRDetect despite excessive APOBEC-related mutagenesis in some 
samples (see Supplementary Fig. 4 for an example). Furthermore, 
HRDetect was able to discern BRCA1/BRCA2-deficient cancers with 
remarkable precision over a wide range of tumor cellularities, includ-
ing for samples with relatively low cellularity (but not less than 15%) 
(Supplementary Fig. 5), where mutation calling sensitivity may be 
compromised. Thus, irrespective of biological or nonbiological noise, 
HRDetect faithfully detects the signal of BRCA1/BRCA2 deficiency, 
reinforcing the exceptional utility of this classifier.
Finally, to advance the potential clinical utility of HRDetect, we 
considered whether HRDetect could be applied earlier in the clinical 
process on small needle biopsy samples rather than post-operatively 
on large specimens. To this end, we obtained 18 DNA samples 
(14 needle biopsies and 4 postoperative tumor block specimens) 
from 9 individuals with triple-negative tumors who were treated with 
neoadjuvant anthracyclines with or without taxanes37 (Supplementary 
Table 9 and Supplementary Note). Although anthracyclines are a 
different compound from PARP inhibitors, sensitivity to anthra-
cyclines has been reported for tumors that show BRCA1/BRCA2 
deficiency38,39. Interestingly, four patients demonstrated complete 
responses to treatment, and all had high HRDetect scores—two were 
confirmed to be germline BRCA1 mutation carriers, and two had 
sporadic tumors (Fig. 5c). In contrast, five patients who exhibited 
residual disease had low HRDetect probability scores. Furthermore, 
HRDetect performed consistently in independent biopsies of tumors 
and in comparison of biopsy and postoperative specimens taken 
from the same patient, without exception. Although the numbers of 
samples are small, in all, these analyses suggest that HRDetect has 
the potential to distinguish therapeutic sensitivity as early in the 
patient’s clinical journey as the first biopsy and is robust between 
independent biopsies and/or specimens. Larger clinical trials are 
clearly necessary to fully understand how this predictor will perform 
when applied to breast cancer diagnostics in general.
Variants of uncertain significance
Germline BRCA1 and BRCA2 SNPs and variants of uncertain 
significance (VUSs), including 20 common alleles and 107 rare or 
private variants, were identified in the data set comprising 560 breast 
cancers (Supplementary Table 4). Fifty-six had concurrent loss 
of the second allele. However, tumors with these variants did not 
consistently demonstrate high scores for BRCA1/BRCA2 deficiency, 
emphasizing that these VUSs are unlikely to be pathogenic and hence 
are of low clinical significance.
There was one exception: PD23563a had a missense mutation in 
BRCA1 encoding p.L1780P with loss of heterozygosity of the other 
allele and a high score for BRCA1/BRCA2 deficiency. This variant 
remains “of uncertain significance” in clinical databases of BRCA1 
SNP alleles (ClinVar), although functional support for defective 
BRCA1 function has been reported40. With only a single example, 
this result must be interpreted with caution, as other causes of 
BRCA1/BRCA2 deficiency in this sample cannot be excluded.
Additionally, eight missense somatic BRCA1 and BRCA2 mutations 
were identified and did not appear to be associated with features of 
deficiency. Over time, HR mutational signatures could be used to 
effectively validate the pathogenicity of VUSs.
HRDetect can distinguish BRCA1- from BRCA2-deficient tumors 
Thus far, we have focused on detecting tumors with either BRCA1 or 
BRCA2 deficiency and not distinguishing between them. Currently, 
there is no clinical indication to separately identify these tumors 
because BRCA1- and BRCA2-deficient tumors are similarly sensitive 
to PARP inhibition. In the future, however, reasons for separating 
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these tumors may arise. The discriminating genomic parameters that 
distinguish BRCA1- from BRCA2-deficient tumors are rearrangement 
signature 3 and deletions without distinctive junctional characteris-
tics (Supplementary Note and Supplementary Fig. 6). Both are best 
detected using WGS approaches.
DISCUSSION
Abrogation of BRCA1 and BRCA2 leads to not only one mutational 
signature but a characteristic set of these signatures. As a predictive 
tool, utilizing these multiple pathogenomic mutational signatures 
is extraordinarily effective, with performance metrics suggesting 
that this method cannot be easily bettered. It dependably detects 
BRCA1/BRCA2 deficiency in the presence of biological noise (for exam-
ple, APOBEC-related mutagenesis), when there is relatively low tumor 
cellularity (Supplementary Note) and when there is nonbiological 
noise from formalin fixation. Demonstrating HRDetect efficacy 
in FFPE-banked samples opens doors in terms of the exploration 
of historic and/or existing clinical trials, assuming that matched nor-
mal DNA samples are also available. Our analyses also emphasize that 
a WGS approach (even at low coverage (tenfold)) is far more effec-
tive than a WES approach at detecting BRCA1/BRCA2 deficiency. 
Additionally, distinguishing BRCA1- from BRCA2-deficient tumors 
is dependent on WGS-based methods. These methodological points 
have implications for the design of the genomic aspects of clinical tri-
als. At least for detecting BRCA1/BRCA2 deficiency, WGS approaches 
are optimal. Our analyses provide support and context for large-scale 
national WGS endeavors such as the UK 100,000 Genomes Project and 
the Precision Medicine Initiative in the United States (see URLs).
While the performance of HRDetect is extremely promising, algorith-
mic developments are also envisaged, including for the identification 
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of tumors that have developed treatment-resistant alleles41,42. 
Historic scars of HR deficiency will be present in a resistant tumor, 
possibly leading to high HRDetect scores. However, distinguish-
ing ongoing from historic mutational signatures of BRCA1/BRCA2  
deficiency is already a possibility, given the advances in exploiting 
the digital nature of modern sequencing technologies to construct 
phylogenetic trees of each person’s tumor30,37.
Although only 22 patients were originally recruited with known 
germline BRCA1- or BRCA2-null cancers, HRDetect reveals an addi-
tional 33 tumors with a germline mutation, 22 tumors with a somatic 
mutation and 47 tumors where no mutation was detected—bringing 
the total number of BRCA1/BRCA2-deficient tumors to 124 (22%). 
Large-scale population-based studies are required to gather proper 
population estimates, but, nevertheless, the numbers are startling.
Most notably, knowledge of the precise causative mutation may 
not be necessary because mutational signatures are such a reli-
able reporter of a tumor’s biological status and, hence, its possible 
sensitivity to PARP inhibition (or other treatments—for example, 
platinum-based salts, anthracyclines and mitomycin C—to which 
cancers with BRCAness are selectively sensitive). Nearly one-third 
of samples that have characteristic genome profiles and high scores for 
BRCA1/BRCA2 deficiency do not have canonical mutations detected. 
Thus, limiting testing to simply sequencing the BRCA1 and BRCA2 
genes and performing methylation assays would miss this cohort 
of patients that could have functional deficiency incurred through 
currently unknown means.
If the tumors with predicted BRCA1/BRCA2 deficiency also dem-
onstrate sensitivity to PARP inhibitors, this would unearth a substan-
tial cohort of patients who could be responsive to selective therapeutic 
agents, which are currently reserved for just ~1–5% of patients with 
breast cancer who are germline mutation carriers. This is potentially 
transformative, and thus the application of this predictor in PARP 
inhibitor clinical trials is warranted to assess predictive capacity in 
clinical settings.
The primary investment of a bank of WGS cancer data has been 
vital to the development of this predictor. Being able to find definitive 
ways of classifying the biological status of a patient’s tumor, potentially 
for therapeutic stratification, is an example of the added value derived 
from these data—instrumental early steps that ultimately could lead 
to population health economic benefits.
URLs. ClinVar, http://www.ncbi.nlm.nih.gov/clinvar/; 100,000 
Genomes Project, https://www.genomicsengland.co.uk/the-100000-
genomes-project/; Precision Medicine Initiative, http://www.cancer.
gov/research/key-initiatives/precision-medicine.
METHODS
Methods, including statements of data availability and any associated 
accession codes and references, are available in the online version of 
the paper.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
ACKNoWLEDGMENTS
This work has been performed on data that were previously published. They 
were generated and funded through the ICGC Breast Cancer Working group by 
the Breast Cancer Somatic Genetics Study (BASIS), a European research project 
funded by the European Community’s Seventh Framework Programme  
(FP7/2010-2014) under grant agreement number 242006; the Triple Negative project 
funded by the Wellcome Trust (grant reference 077012/Z/05/Z) and the HER2+ 
project funded by Institut National du Cancer (INCa) in France (grants 226-2009, 
02-2011, 41-2012, 144-2008, 06-2012). The ICGC Asian Breast Cancer Project was 
funded through a grant of the Korean Health Technology R&D Project, Ministry  
of Health & Welfare, Republic of Korea (A111218-SC01). The Oslo Breast Cancer 
Research Consortium (OSBREAC), Norway (http://www.osbreac.no/),  
contributed samples to the study. D.G. was supported by the EU-FP7-
SUPPRESSTEM project. A.L.R. is partially supported by the Dana-Farber/Harvard 
Cancer Center SPORE in Breast Cancer (NIH/NCI 5 P50 CA168504-02). A.S. was 
supported by Cancer Genomics Netherlands (CGC.nl) through a grant from the 
Netherlands Organisation of Scientific research (NWO). C.S. is supported by a 
grant from the Breast Cancer Research Foundation. E.B. was funded by EMBL.  
A.T. acknowledges infrastructure support funding from the NIHR Biomedical 
Research Centres at Guy’s and St Thomas’ and Royal Marsden Hospital NHS 
Foundation Trusts. G.K. is supported by National Research Foundation of Korea 
(NRF) grants funded by the Korean government (NRF 2015R1A2A1A10052578). 
S.N.-Z. is a Wellcome Beit Fellow and personally funded by a Wellcome Trust 
Intermediate Fellowship (WT100183MA). Finally, we would like to acknowledge 
all members of the ICGC Breast Cancer Working Group and ICGC Asian Breast 
Cancer Project, for without the foresight of engaging in this scale of collaboration 
we would not have gained these insights.
AUTHoR CoNTRIBUTIoNS
H.D., D.G. and S.N.-Z. drove the development of the intellectual concepts, 
performed analyses and wrote the manuscript. S. Morganella, J.S., X.Z. and  
M.R. contributed towards data curation and performed analyses. L.R.Y., S.B., 
A.M.S., P.T.S., T.A.K., J.E.E., P.N.S., S.R.L., A.V.-S., C.S., A.T., A.M.T. and S.V.L. 
contributed new samples and/or to experimental design of the study. S. Martin  
was the scientific project coordinator. K.R. provided bioinformatics support.  
P.J.C. provided infrastructure at the Wellcome Trust Sanger Institute. G.K., A.B., 
E.B., H.G.S., M.J.v.d.V., A.-L.B.-D., J.W.M.M., A.M.T., A.L.R., A.V. and M.R.S. 
originally conceived the concept of the Breast Cancer Consortium that generated 
the data resource that has been utilized for these analyses, contributed old and new 
samples, and contributed comments towards the manuscript. 
COMPETING FINANCIAL INTERESTS
The authors declare competing financial interests: details are available in the online 
version of the paper.
1.
 
Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and 
BRCA2 mutations in a population-based series of breast cancer cases. Br. J. Cancer
 
83, 1301–1308 (2000).
2.
 
John, E.M. et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US 
racial/ethnic groups. J. Am. Med. Assoc.
 
298, 2869–2876 (2007).
3.
 
Malone, K.E. et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in 
a population-based study of breast cancer in white and black American women 
ages 35 to 64 years. Cancer Res.
 
66, 8297–8308 (2006).
4.
 
Couch, F.J., Nathanson, K.L. & Offit, K. Two decades after BRCA: setting 
 
paradigms in personalized cancer care and prevention. Science
 
343, 1466–1470 
(2014).
5.
 
King, M.C. “The race” to clone BRCA1. Science
 
343, 1462–1465 (2014).
6.
 
Lord, C.J. & Ashworth, A. The DNA damage response and cancer therapy. Nature
 
481, 287–294 (2012).
7.
 
Venkitaraman, A.R. Cancer suppression by the chromosome custodians, BRCA1 and 
BRCA2. Science
 
343, 1470–1475 (2014).
8.
 
Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a 
therapeutic strategy. Nature
 
434, 917–921 (2005).
9.
 
Prakash, R., Zhang, Y., Feng, W. & Jasin, M. Homologous recombination and human 
health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. 
Perspect. Biol.
 
7, a016600 (2015).
10.
 
Bryant, H.E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of 
poly(ADP-ribose) polymerase. Nature
 
434, 913–917 (2005).
11.
 
Fong, P.C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA
 
mutation carriers. N. Engl. J. Med.
 
361, 123–134 (2009).
12.
 
Audeh, M.W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients 
with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept 
trial. Lancet
 
376, 245–251 (2010).
13.
 
Tutt, A. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with 
BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. 
Lancet
 
376, 235–244 (2010).
14.
 
Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. 
 
N. Engl. J. Med.
 
373, 1697–1708 (2015).
15.
 
Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed 
ovarian cancer. N. Engl. J. Med.
 
366, 1382–1392 (2012).
16.
 
Lips, E.H. et al. Quantitative copy number analysis by Multiplex Ligation–dependent 
Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies 
BRCAness. Breast Cancer Res.
 
13, R107 (2011).
   
17. Ruscito, I. et al. BRCA1 gene promoter methylation status in high-grade serous 
ovarian cancer patients—a study of the Tumour Bank Ovarian Cancer (TOC) and 
Ovarian Cancer Diagnosis consortium (OVCAD). Eur. J. Cancer 50, 2090–2098 
(2014).
18. Jazaeri, A.A. et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and 
sporadic ovarian cancers. J. Natl. Cancer Inst. 94, 990–1000 (2002).
19. Larsen, M.J. et al. Classifications within molecular subtypes enables identification 
of BRCA1/BRCA2 mutation carriers by RNA tumor profiling. PLoS One 8, e64268 
(2013).
20. Peng, G. et al. Genome-wide transcriptome profiling of homologous recombination 
DNA repair. Nat. Commun. 5, 3361 (2014).
21. Joosse, S.A. et al. Prediction of BRCA1-association in hereditary non-BRCA1/2 
breast carcinomas with array-CGH. Breast Cancer Res. Treat. 116, 479–489 
(2009).
22. Vollebergh, M.A. et al. An aCGH classifier derived from BRCA1-mutated breast 
cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative 
breast cancer patients. Ann. Oncol. 22, 1561–1570 (2011).
23. Watkins, J.A., Irshad, S., Grigoriadis, A. & Tutt, A.N. Genomic scars as biomarkers 
of homologous recombination deficiency and drug response in breast and ovarian 
cancers. Breast Cancer Res. 16, 211 (2014).
24. Graeser, M. et al. A marker of homologous recombination predicts pathologic 
complete response to neoadjuvant chemotherapy in primary breast cancer. 
Clin. Cancer Res. 16, 6159–6168 (2010).
25. Lord, C.J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110–120 
(2016).
26. Bentley, D.R. et al. Accurate whole human genome sequencing using reversible 
terminator chemistry. Nature 456, 53–59 (2008).
27. Nik-Zainal, S. et al. Landscape of somatic mutations in 560 breast cancer whole-
genome sequences. Nature 534, 47–54 (2016).
28. Morganella, S. et al. The topography of mutational processes in breast cancer 
genomes. Nat. Commun. 7, 11383 (2016).
29. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast 
cancers. Cell 149, 979–993 (2012).
30. Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 
(2012).
31. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 
500, 415–421 (2013).
32. Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic 
cancer. Nature 518, 495–501 (2015).
33. Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. 
Nature 531, 47–52 (2016).
34. Patch, A.M. et al. Whole-genome characterization of chemoresistant ovarian cancer. 
Nature 521, 489–494 (2015).
35. Alexandrov, L.B., Nik-Zainal, S., Siu, H.C., Leung, S.Y. & Stratton, M.R. A mutational 
signature in gastric cancer suggests therapeutic strategies. Nat. Commun. 6, 8683 
(2015).
36. Stefansson, O.A. et al. Genomic and phenotypic analysis of BRCA2 mutated breast 
cancers reveals co-occurring changes linked to progression. Breast Cancer Res. 13, 
R95 (2011).
37. Yates, L.R. et al. Subclonal diversification of primary breast cancer revealed by 
multiregion sequencing. Nat. Med. 21, 751–759 (2015).
38. Rodriguez, A.A. et al. DNA repair signature is associated with anthracycline response 
in triple negative breast cancer patients. Breast Cancer Res. Treat. 123, 189–196 
(2010).
39. Chappuis, P.O. et al. A significant response to neoadjuvant chemotherapy in 
BRCA1/2 related breast cancer. J. Med. Genet. 39, 608–610 (2002).
40. Lee, M.S. et al. Comprehensive analysis of missense variations in the BRCT domain 
of BRCA1 by structural and functional assays. Cancer Res. 70, 4880–4890 (2010).
41. Edwards, S.L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. 
Nature 451, 1111–1115 (2008).
42. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in 
BRCA2-mutated cancers. Nature 451, 1116–1120 (2008).
1Wellcome Trust Sanger Institute, Hinxton, UK. 2Guy’s and St Thomas’ NHS Trust, London, UK. 3Division of Oncology and Pathology, Department of Clinical  
Sciences Lund, Lund University, Lund, Sweden. 4Oncology, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Little Chesterford, UK. 
5Translational Research Lab Department, Centre Léon Bérard, Lyon, France. 6Department of Medical Oncology, Erasmus MC Cancer Institute and Cancer Genomics, 
Erasmus University Medical Center, Rotterdam, the Netherlands. 7Centre for Clinical Research and School of Medicine, The University of Queensland, Brisbane, 
Queensland, Australia. 8Memorial Sloan Kettering Cancer Center, New York, New York, USA. 9Cancer Research Laboratory, Faculty of Medicine, University of Iceland, 
Reykjavik, Iceland. 10Department of Pathology, College of Medicine, Hanyang University, Seoul, Republic of Korea. 11European Molecular Biology Laboratory, 
European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, UK. 12Department of Molecular Biology, Faculties of Science and Medicine, Radboud 
University, Nijmegen, the Netherlands. 13Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands. 14Department of Cancer Genetics, 
Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. 15K.G. Jebsen Centre for Breast Cancer Research, Institute 
for Clinical Medicine, University of Oslo, Oslo, Norway. 16Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. 
17Department of Laboratory Medicine, Radboud University Medical Center, Nijmegen, the Netherlands. 18Pathology Queensland, Royal Brisbane and Women’s 
Hospital, Brisbane, Queensland, Australia. 19Department of Pathology, Institut Curie, Paris, France. 20INSERM U934, Institut Curie, Paris, France. 21Breast Cancer 
Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium. 22Breast Cancer Now Research Unit, King’s College, 
London, UK. 23Breast Cancer Now Toby Robin’s Research Centre, Institute of Cancer Research, London, UK. 24Department of Breast Surgical Oncology, University 
of Texas MD Anderson Cancer Center, Houston, Texas, USA. 25Translational Cancer Research Unit, Center for Oncological Research, Faculty of Medicine and 
Health Sciences, University of Antwerp, Antwerp, Belgium. 26HistoGeneX, Wilrijk, Belgium. 27Department of Pathology, Brigham and Women’s Hospital, Boston, 
Massachusetts, USA. 28Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 29Equipe Erable, INRIA Grenoble-Rhône-Alpes, Montbonnot-Saint Martin, 
France. 30Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France. 31East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Foundation Trust, 
Cambridge, UK. 32These authors contributed equally to this work. Correspondence should be addressed to S.N.-Z. (snz@sanger.ac.uk).
ONLINE METHODS
Data set. The internal review boards of each participating institution approved 
collection and use of samples of all patients in this study. Informed consent was 
obtained by the relevant participating institution.
DNA was extracted from 560 individuals (556 females and 4 males) with 
breast cancer from both tumor and corresponding normal tissue and samples 
were subjected to whole-genome sequencing as described previously27. Resulting 
BAM files were aligned to the reference human genome (GRCh37) using 
Burrows–Wheeler aligner, BWA (v0.5.9)43.
Mutation calling was performed as described previously27. Briefly, CaVEMan 
(Cancer Variants Through Expectation Maximization; http://cancerit.github.
io/CaVEMan/) was used to call somatic substitutions. Indels in the tumor and 
normal genomes were called using modified Pindel version 2.0 (http://cancerit.
github.io/cgpPindel/) on the NCBI37 genome build44. Structural variants were 
discovered using a bespoke algorithm, BRASS (BReakpoint AnalySiS) (https://
github.com/cancerit/BRASS) through discordantly mapping paired-end reads 
followed by de novo local assembly using Velvet45 to determine exact coordinates 
and features of breakpoint junction sequence.
In total, 3,479,652 somatic base substitutions, 371,993 small indels and 
77,695 rearrangements were detected in the 560 samples27.
Mutational signatures background. Mutation signature analysis based on 
non-negative matrix factorization (NMF) was performed as described 
previously27,46. Twelve consensus base-substitution signatures were identi-
fied previously in the 560 breast whole genomes: signatures 1, 2, 3, 5, 6, 8, 13, 
17, 18, 20, 26 and 30.
Base-substitution signatures 1 (characterized by C>T transitions at NCG, 
where the underlined base is mutated) and 5 (primarily characterized by C>T 
and T>C mutations) have previously been associated with age47. Both signature 
2, which is predominantly composed of C>T substitutions at TCN, and signature 
13, which predominantly comprises C>G mutations at TCN, may be generated 
by members of the AID/APOBEC family of cytidine deaminases that deaminate 
cytosine to uracil. Signatures 3 (enriched in C>G substitutions) and 8 (enriched 
in C>A substitutions) both lack highly distinctive substitution features and are 
enriched in BRCA1- and BRCA2-null tumors. Signature 3 in particular has been 
associated with the presence of inactivating BRCA1 and BRCA2 mutations. 
Signatures 6, 20 and 26 are associated with defective DNA mismatch repair and 
were restricted to 10 samples, which exhibited mutation profiles consistent with 
mismatch repair deficiency. The etiology of signatures 17 (characterized by T>G 
mutations at NTT) and 18 (exhibiting a high proportion of C>A mutations) is 
unknown. Signature 30 (characterized by C>T transitions) was found in a single 
patient and may be due to previous exposure to cancer therapies.
Six rearrangement mutational signatures (RS1–RS6) based on rearrange-
ment type, clustering and size were identified27. RS1 and RS3 were characterized 
by nonclustered tandem duplications. RS1 had mostly tandem duplications 
of >100 kb, while RS3 was predominantly associated with small tandem 
duplications of <10 kb. RS2 was characterized by nonclustered deletions 
(>100 kb), inversions and interchromosomal translocations. RS4 was charac-
terized by clustered interchromosomal translocations. RS5 was associated with 
nonclustered deletions of <100 kb, while RS6 contained clustered inversions and 
deletions. RS5 is enriched in BRCA1/BRCA2-null tumors, and an excess of RS3 
is observed in BRCA1-null tumors27.
Two indel signatures, based on the presence of either short tandem repeats 
or short stretches of identical sequence at the breakpoints (termed overlapping 
microhomology), were also extracted. Deletions with microhomology were 
typically >3 bp in length and are characteristic of defective nonhomologous- 
end-joining-based DNA double-strand break repair, whereas indels at short 
tandem repeats are typical of the microsatellite instability associated with 
defective DNA mismatch repair. See Supplementary Table 1 for the breakdown 
of the contribution of each mutation signature per sample.
Determining whether a sample had particular mutational signatures. An itera-
tive algorithm was used to identify the set of COSMIC signatures (http://cancer.
sanger.ac.uk/cosmic/signatures) active in each sample (the so-called ‘exposure’). 
Each sample was completely described by a vector containing the number of 
substitutions observed for each mutation and flanking sequence context (defined 
by the neighboring bases immediately 5′ and 3′ to the mutated base and by the 
mutated base itself). Each mutation was oriented with respect to the pyrimidine 
strand, and, consequently, each vector contained 96 elements. The algorithm 
started from an initial solution estimated by using a simulated annealing-based 
method. Then, mutations were iteratively reassigned to alternative signatures, 
and cosine similarities were obtained by comparing the reconstructed 96-ele-
ment vector for each potential reassignment to that of the observed 96-element 
vector with the aim of identifying the highest possible cosine similarity value 
that was possible. The algorithm stopped when no improvement to the cosine 
similarity was found.
HRD indices. Single-nucleotide polymorphism (SNP) array hybridization 
using the Affymetrix SNP6.0 platform was performed according to Affymetrix 
protocols. Allele-specific copy number analysis of tumors was performed 
using ASCAT (v2.1.1) to generate integral allele-specific copy number profiles 
for the tumor cells48. ASCAT was also applied to next-generation sequencing 
data directly, producing highly comparable results. Resulting allele-specific data 
generated by ASCAT were used in the calculation of the homologous recom-
bination deficiency (HRD) index score using implementations made in R49,50. 
See Supplementary Table 1 for HRD index scores.
Variants in BRCA1 and BRCA2 and other HR genes. For details of the proc-
ess used to discover germline and somatic mutations in BRCA1/BRCA2 and 
other genes known to be involved in DNA repair via homologous recombination, 
see the Supplementary Note.
Lasso logistic regression modeling. Learning phase. We set out to create 
a method for detecting genomic features associated with deficiency in 
BRCA1/BRCA2 that would report the probability of a tumor sample being 
HR deficient during its evolution.
The method is trained on whole-genome sequencing data. We utilized the 
information on the signatures of single base substitutions, indels and rearrange-
ments and a copy number classification based on HRD indices.
This supervised learning method was first applied to a cohort of 22 carriers 
of germline BRCA1 and BRCA2 mutations with clear loss of the other parental 
allele. There were also 235 control samples that did not have BRCA1/BRCA2 
mutations or promoter hypermethylation of BRCA1, or any evidence of 
signatures of BRCA1/BRCA2 deficiency, and were believed to be sporadic 
breast cancers. BRCA1/BRCA2-proficient tumors are usually reported as rela-
tively stable genomically and quiescent in mutational profile. Thus, using this 
prior knowledge, we manually interrogated genome plots of the overall muta-
tion patterns to identify the 235 samples that we could confidently call BRCA- 
proficient tumors.
Inputs into the algorithm were as follows: (i) counts of mutations associ-
ated with each signature of single-base substitutions: signatures 1, 2, 3, 5, 6, 8, 
13, 17, 18, 20 and 26 (signature 30 was excluded as it involved only 1 sample), 
(ii) indels with microhomology at the indel breakpoint junction, indels at 
polynucleotide-repeat tracts and other complex indels as proportions, 
(iii) counts of rearrangements associated with each signature of rearrangements 
RS1–RS6 and (iv) HRD index.
Some samples had vastly higher counts of substitutions than others, 
and such outliers posed a challenge in the analysis. Thus, the genomic 
features were first log transformed, according to the following formula. 
′ = +x ln( )x 1
The ranges of values for each class of mutation were vastly different. 
Therefore, the transformed data were normalized so that each feature had a 
mean of 0 and s.d. of 1, in order to be able to make the features comparable 
to one another. 
′′ =
′ − ′
′
x
mean
s d
x x
x
( )
. .( )
A lasso logistic regression51 model was used to identify the genomic features 
that could distinguish the two categories of patient samples: those affected and 
those not affected by BRCA1/BRCA2 deficiency. An efficient computer implemen-
tation for learning model parameters was available through the R package glmnet. 
The lasso approach permits learning and weighting of the genomic features most 
relevant to predicting BRCA1/BRCA2 status through variable selection.
(1)
(2)
β coefficients, also referred to as weights, are learned from the genomic fea-
tures of BRCA1/BRCA2-proficient and BRCA1/BRCA2-deficient samples pre-
sented to the algorithm. Optimal coefficients are obtained by minimizing the 
objective function51 
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where yi is the BRCA status of a sample: yi = 1 for BRCA1/BRCA2-null samples, 
yi = 0 otherwise; β0 is the intercept, interpreted as the log of odds of yi = 1 when 
xiT = 0; β is a vector of weights, each corresponding to a genomic feature; p is the 
number of features characterizing each sample; N is the number of samples; xi
T  
is the vector of features characterizing the ith sample; λ is the penalty promoting 
the sparseness of the weights, as learned through nested cross-validation; and 
||β||1 is the L1 norm of the vector of weights (i.e., the sum of the absolute values 
of all entries of the coefficient vector)
We constrained all β weights to be positive because they reflect the biological 
presence of mutational processes that are due to (in this case) BRCA1/BRCA2 
deficiency. By setting the constraint of nonnegative weights, we ensured that 
all samples would be scored on the basis of the presence of relevant mutational 
signatures associated with BRCA1/BRCA2 deficiency, irrespective of whether 
these signatures are the dominant mutational process in the cancer.
Multiple mutational processes can exist in a tumor, and, in some cases, certain 
hypermutator mutational phenotypes can come to dominate a specific cancer 
and eclipse the appreciation of other mutational processes. However, using non-
negative coefficients in our model ensures that mutational signatures associated 
with BRCA1/BRCA2 deficiency are detected reliably no matter how weakly they 
are present.
Ultimately, the lasso logistic regression model is used to assign a probabilistic 
score to any new sample that is being analyzed, using the normalized expo-
sures of mutational processes in the sample (xi
T) and applying the parameters of 
the model (β) as follows 
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where Ci is the variable encoding the status of the ith sample; β0 is the inter-
cept weight; xi
T  is the vector encoding features of the ith sample; and β is the 
vector of weights.
Robustness, stability and generalizability (on 22). We trained the logistic 
regression model using a cohort of 22 germline BRCA1/BRCA2 mutation car-
riers with loss of the second allele and a cohort of 235 sporadic tumors in this 
supervised analysis.
We used a tenfold nested cross-validation strategy to assess the robustness 
and generalizability of the learned weights. Ten outer folds were used in the 
cross-validation process where 10% of data were set aside for each outer fold 
and were used to assess the accuracy of the prediction and generalizability.
The remaining 90% of the data were used for model parameter selection. 
The parameters associated with BRCA1/BRCA2 deficiency were investigated on 
the inner folds for a range of λ values that define the sparsity of the results.
We obtained the model coefficients across the ten folds (presented as box 
plots in Supplementary Fig. 7), demonstrating that the results across the ten 
folds are consistently nonzero for each of the genomic parameters identified as 
distinguishing. The model was finally applied across all the data used in train-
ing, with the coefficients from this final run (Supplementary Table 10) also 
presented as red crosses in Supplementary Figure 7.
The genomic parameters and associated coefficients were identified for a λ 
value of 0.000480 (mean, 0.000891; s.d., 0.000803), to distinguish samples with 
HR deficiency in the final step.
Finally, we assessed the stability of each coefficient through subsampling of 
the training set. We chose half of samples in the training set randomly and 
counted how many times each genomic feature was selected as a distinguishing 
feature (i.e., had a nonzero coefficient). This was performed iteratively; out 
(3)
(4)
of 100 subsampling and training iterations, each coefficient was nonzero 
(Supplementary Table 11).
While most features are relatively stable, rearrangement signature RS3, which 
is a feature of BRCA1-null tumors, appears to be less stable. This lower stabil-
ity is likely due to the cohort of 22 informative tumors that were chosen to 
represent BRCA1/BRCA2 nullness. Only 5 of the 22 patients are BRCA1-null 
patients; thus, there is a skew in the cohort to BRCA2, and the balance in this 
cohort could be improved as a means to improve the learned weights and their 
relative stability.
Identifying further samples with BRCA1/BRCA2 deficiency. The logistic regres-
sion model was applied to all 560 samples in the cohort. In particular, we could 
calculate the BRCAness scores on samples that were not in the training set, for 
example, because their genomes were not quiescent or had uncertain genomic 
profiles. Supplementary Figure 2 shows the scores for each sample, demonstrat-
ing a steep sigmoidal curve.
Apart from the 22 individuals recruited into the study, many individuals with 
high BRCAness scores had germline mutations that we had not known of at the 
time of their enrollment into the study, and many had somatic BRCA1/BRCA2 
mutations. All had loss of the other parental allele. We thus reasoned that features 
of BRCAness are present in samples with biallelic inactivation of BRCA1 and 
BRCA2 genes, whether germline or somatic, and included all such samples in 
a further round of training.
Retraining on 77 samples and defining HRDetect, a classifier of BRCA1/BRCA2 
deficiency. In the final round of training, we included 77 samples with biallelic 
inactivation of BRCA1/BRCA2 and 234 quiescent tumors as negative examples. 
The number of BRCA1/BRCA2-proficient tumors differs by one sample between 
this and the previous training round because one of the samples with a quies-
cent genome, PD6042a, was subsequently found to have a biallelic mutation 
of BRCA2. We assessed the robustness and generalizability of HRDetect using 
nested cross-validation as before (see Online Methods, “Robustness, stability 
and generalizability (on 22)”).
The genomic parameters and associated coefficients learned across the ten 
folds of cross-validation are shown in Supplementary Figure 8. The box plots 
show the variability of each coefficient, and the red crosses show the values of 
the coefficients when training on the whole data set.
In comparison to training with only 22 known carriers of germline BRCA1/
BRCA2 mutations, the variability of the coefficient values across folds was 
decreased. A larger number of informative samples in the training set improved 
the robustness of the coefficients.
With the higher number of training samples, the stability of individual 
coefficients also improved, as shown in Supplementary Table 12.
The logistic regression model was settled on the coefficients in Supplementary 
Table 13, with λ of 0.00369 (mean, 0.00478; s.d., 0.00104).
The accuracy of the BRCA predictions was excellent, with an area 
under the curve in cross-validation of 1 for the 77 BRCA1/BRCA2-null 
samples and 234 quiescent tumors (311 samples from the 560 breast 
cancer genomes).
We also explored the possibility of permitting interactions between all genomic 
covariates in order to discover potentially augmented effects from cooperating 
signatures in our model (for details, see the Supplementary Note).
Assessment of the accuracy of the classifiers through ROC curves. For a more 
comprehensive assessment of the accuracy of HRDetect, we extended the set 
of samples by 60 samples that had been excluded from training. We applied 
HRDetect to all samples that had been successfully characterized with respect 
to methylation and HRD indices. We ultimately assessed the performance of 
HRDetect on 371 of the 560 breast cancer genomes, ignoring 2 samples with no 
HRD index and 187 samples with missing methylation data, as their BRCA1/
BRCA2 status could not be verified.
In calculating the ROC curves, we compared the predictions from 
HRDetect for each of the 371 samples against evidence of biallelic loss 
of BRCA1/BRCA2. The area under the ROC curve for the breast cancer 
genomes was 0.98.
Finally, HRDetect was applied to the full set of 560 breast cancer samples 
to give the final HRDetect score for each sample.
The flow diagram in Supplementary Figure 9 describes the steps involved 
in training, evaluation and application of HRDetect to the full data set.
Applying HRDetect to new tumor samples. Applying the predictor to a new 
sample requires characterization of the sample with respect to the signatures 
of single-base substitutions, rearrangements, copy number profile and HRD 
score, and small insertions and deletions together with the characteristics of 
adjacent sequence.
Furthermore, the features of a new sample need to be normalized as 
in equations (1) and (2). See Supplementary Table 14 for the means and 
s.d. of each feature that were taken into account based on current settings 
of HRDetect.
After the features of a new sample were normalized, the HRDetect score was 
obtained by applying equation (4), coefficients from Supplementary Table 13 
and intercept β0 = −3.364.
For details of how HRDetect was applied to new breast cancer samples, 
downsampled genomes, and breast cancer WES and WGS data from other 
cancer types, see the Supplementary Note.
Data availability. Breast cancer whole-genome sequence BAM files and 
CEL files from Affymetrix SNP6 arrays are available from the European 
Genome-phenome Archive (EGA).
The overarching EGA accession number for the 560 breast cancers used in 
the initial development of HRDetect is EGAS00001001178. This includes both 
whole-genome sequence BAM files and SNP6 array CEL files.
The accession numbers for the 80 additional breast cancers used for validation 
are EGAD00001002740 (sequence BAM files) and EGAD00010001079 (SNP6 
array CEL files).
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